Sermorelin (5mg & 10mg)

Sermorelin (5mg): Growth Hormone-Releasing Hormone (GHRH) Analogue — the 29-Amino-Acid N-Terminal Fragment of Human GHRH (1-29 NH2), Sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-NH2, the Minimal Biologically Active Fragment of GHRH That Stimulates Pituitary Growth Hormone Release in a Physiological, Pulsatile Manner — Used in Research for Growth Hormone Deficiency, Anti-Aging, Body Composition, Recovery, and Metabolic Health

Sermorelin is a synthetic 29-amino-acid peptide that represents the N-terminal biologically active fragment of human growth hormone-releasing hormone (GHRH) — specifically, GHRH (1-29) with an amidated C-terminus (1-29 NH2). Its sequence is Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-NH2. Full-length human GHRH is a 44-amino-acid peptide (also existing as a 40-amino-acid form due to alternative splicing) produced by neuroendocrine neurons in the arcuate nucleus of the hypothalamus; it is released into the hypophyseal portal circulation to stimulate growth hormone (GH) secretion from somatotroph cells in the anterior pituitary gland. However, the full 44-amino-acid peptide is rapidly degraded by peptidases (particularly dipeptidyl peptidase IV [DPP-IV], which cleaves the N-terminal Tyr-Ala dipeptide, inactivating the peptide within minutes). Research demonstrated that the first 29 amino acids of GHRH contain the full biological activity for GH release — this minimal active fragment is called Sermorelin (GHRH 1-29 NH2). The C-terminal amidation (NH2) further enhances stability and receptor binding affinity compared to the free acid form. Sermorelin was developed in the 1970s-1980s (following the discovery and sequencing of GHRH from pancreatic tumors in 1982 by Guillemin and colleagues) and was FDA-approved in 1997 under the brand name Geref for the diagnosis and treatment of growth hormone deficiency (GHD) in children (idiopathic GHD or GHD secondary to pituitary disease). However, Geref was subsequently withdrawn from the US market in 2008 by the manufacturer (EMD Serono) for commercial reasons (not safety concerns) — it remains available in some other countries and as a research-grade compound. Sermorelin functions as a GHRH receptor agonist, binding to the GHRH receptor (GHRHR, a G-protein-coupled receptor [GPCR] of the secretin/glucagon/VIP family) on pituitary somatotrophs, activating the cAMP/PKA signaling pathway, which stimulates GH synthesis and release. Importantly, Sermorelin stimulates GH release in a physiological, pulsatile manner that preserves the natural negative feedback regulation (unlike exogenous recombinant human GH [rhGH], which directly elevates GH levels and suppresses endogenous pituitary function). This physiological stimulation is a key advantage: Sermorelin enhances the body's own GH production rather than replacing it, potentially preserving pituitary responsiveness and reducing the risk of desensitization or suppression. Sermorelin has been extensively studied in clinical trials for: (1) Pediatric growth hormone deficiency — FDA-approved (formerly Geref), demonstrated efficacy in increasing growth velocity and height in GHD children; (2) Adult-onset GHD and age-related GH decline (somatopause) — studies show Sermorelin can increase GH and IGF-1 levels in older adults, improving body composition (reduced fat mass, increased lean mass), skin quality, energy, sleep quality, and overall well-being; (3) Anti-aging and longevity research — GH/IGF-1 pathway modulation is a major focus of aging research; Sermorelin's physiological stimulation may offer benefits with fewer side effects than exogenous GH; (4) Body composition and fitness — used in research for fat loss, muscle preservation/gain, recovery from exercise, and metabolic health; (5) Recovery and healing — GH/IGF-1 play roles in tissue repair, wound healing, and recovery from injury/surgery; (6) Sleep quality — GH is primarily released during deep sleep (slow-wave sleep); Sermorelin may enhance sleep-related GH pulses and improve sleep architecture; (7) Cardiometabolic health — GH/IGF-1 influence lipid profiles, insulin sensitivity, body composition, and cardiovascular function; (8) Bone health — GH/IGF-1 are important for bone mineral density and bone turnover. In research settings, Sermorelin is often compared and combined with GHRP (growth hormone-releasing peptide) family compounds (GHRP-2, GHRP-6, Hexarelin, Ipamorelin) — GHRPs act through a different receptor (the ghrelin receptor / GHS-R1a) and have a synergistic effect with GHRH analogues like Sermorelin; the combination of Sermorelin + GHRP is a well-known research stack for potent, physiological GH stimulation (often called "the GHRH + GHRP synergy"). Sermorelin is typically administered by subcutaneous (SC) injection (the most common route, typically before bedtime to align with natural nocturnal GH pulses, or in divided doses). It is NOT orally active (peptide degraded by GI proteases). The 5mg vial format provides a convenient quantity for research use. Sermorelin is generally well-tolerated with a favorable safety profile — common side effects are usually mild and transient, including injection site reactions (pain, redness, swelling), transient flushing, headache, dizziness, nausea, mild hyperactivity or fatigue, and (at higher doses or with long-term use) potential effects related to elevated GH/IGF-1 such as water retention/edema, joint pain/arthralgia, muscle aches, carpal tunnel syndrome symptoms, and (in susceptible individuals) potential effects on glucose metabolism/insulin sensitivity. Rare but serious considerations include: potential stimulation of pituitary tumors (use caution in patients with known or suspected pituitary neoplasia — Sermorelin should not be used in patients with active malignancy, particularly pituitary tumors), hypersensitivity reactions, and (with high-dose long-term use) potential acromegaly-like changes (though these are far less likely with physiological GHRH stimulation than with high-dose exogenous GH). Contraindications include: known hypersensitivity to Sermorelin or GHRH, active malignancy (particularly pituitary tumors), pregnancy and breastfeeding (insufficient safety data), and (with caution) diabetes/insulin resistance (monitor glucose), hypothyroidism (may require thyroid monitoring/replacement), and conditions where GH stimulation may be problematic. As of 2026, Sermorelin is NOT currently marketed as a prescription drug in the US (Geref was withdrawn in 2008), though it remains available as a research-grade compound and is used off-label/compounded in some anti-aging and wellness clinics (subject to regulatory considerations — compounded Sermorelin has been subject to FDA enforcement actions in some contexts). The research-grade Sermorelin supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Research Perspective: Sermorelin (GHRH 1-29 NH₂) is unique among GH-releasing compounds because it stimulates the body's own pituitary to release GH in a natural, pulsatile pattern — rather than directly elevating circulating GH levels as recombinant human GH (rhGH) does. This physiological mechanism preserves the hypothalamic-pituitary negative feedback loop, meaning Sermorelin is less likely to cause pituitary suppression, desensitization, or the supraphysiological GH spikes associated with exogenous GH therapy. The trade-off is that Sermorelin's GH-releasing effect is dependent on pituitary reserve — it works best when the pituitary somatotrophs are still functional (as in age-related decline or mild GHD), and may be less effective in cases of severe pituitary damage or complete GHD. In research, Sermorelin is often used as a "GH secretagogue" that works with the body's natural rhythms — typically administered before bedtime to augment the natural nocturnal GH pulse that occurs during slow-wave sleep.

Clinical History: Sermorelin received FDA approval in 1997 (Geref®) for the diagnosis and treatment of pediatric growth hormone deficiency, representing the first GHRH analogue approved for therapeutic use. It was withdrawn from the US market in 2008 for commercial reasons (not safety concerns). It remains a subject of research for adult GHD, age-related GH decline (somatopause), body composition, recovery, and cardiometabolic health, and is available as a research-grade compound.

Key Research Applications and Evidence Base

• Pediatric Growth Hormone Deficiency (GHD) — FDA-approved (formerly Geref): Sermorelin was the first GHRH analogue approved by the FDA (1997) for the diagnosis and treatment of idiopathic GHD or GHD secondary to pituitary disease in children. Clinical trials demonstrated that daily subcutaneous Sermorelin injections (typically 0.03 mg/kg/day, or ~30 mcg/kg/day) significantly increased growth velocity and height in GHD children over 6-12 months of treatment, with efficacy comparable to (though slightly less potent than) recombinant human GH (rhGH) therapy. The advantage of Sermorelin over rhGH in pediatric GHD includes: physiological GH stimulation (preserving pituitary function), lower risk of GH excess side effects, and potential for preserving endogenous GH production. However, Sermorelin requires a functional pituitary (somatotroph reserve) — it is less effective in severe pituitary damage. Sermorelin was also used as a diagnostic agent (the "Sermorelin stimulation test") to assess pituitary GH reserve — a single IV bolus of Sermorelin (1 mcg/kg) stimulates GH release, and the GH response curve helps distinguish hypothalamic from pituitary causes of GHD. Geref was withdrawn from the US market in 2008 by EMD Serono for commercial/business reasons (not due to safety concerns), but Sermorelin remains available as a research-grade compound and in some other countries^[1][2].
• Adult-Onset GHD and Age-Related GH Decline (Somatopause): Growth hormone secretion naturally declines with age — by age 60, GH production may be 50-70% lower than in young adulthood (this age-related decline is called "somatopause"). This decline is associated with: increased abdominal/visceral fat, decreased lean muscle mass, reduced bone density, decreased skin thickness/elasticity, reduced energy and vitality, impaired sleep quality, decreased exercise capacity, and adverse changes in lipid profiles and insulin sensitivity. Clinical studies of Sermorelin in older adults (50-75+ years) with age-related GH decline or adult GHD have demonstrated: (1) Increased GH and IGF-1 levels — Sermorelin (typically 0.5-1 mg SC at bedtime, or 200-500 mcg/day) significantly increases 24-hour GH secretion and serum IGF-1 levels, often restoring them toward youthful ranges without causing supraphysiological spikes; (2) Improved body composition — reduced fat mass (particularly abdominal/visceral fat), increased lean body mass, improved muscle-to-fat ratio; effects are typically modest (more fat loss than muscle gain) and develop over 3-6 months; (3) Improved skin and connective tissue — increased skin thickness, improved skin elasticity and hydration, reduced wrinkle depth (GH/IGF-1 stimulate collagen and elastin production); (4) Improved sleep quality — enhanced slow-wave (deep) sleep, increased sleep-related GH pulses, improved sleep architecture and daytime alertness; (5) Increased energy and vitality — improved subjective energy levels, exercise capacity, and overall well-being; (6) Bone health — increased bone turnover markers, potential improvement in bone mineral density with long-term use (GH/IGF-1 are anabolic for bone); (7) Cardiometabolic effects — improved lipid profiles (reduced LDL, triglycerides; increased HDL in some studies), improved body composition (which benefits insulin sensitivity), though effects on glucose are mixed (GH can be diabetogenic at high doses, but physiological Sermorelin stimulation may have neutral or beneficial effects on insulin sensitivity through fat loss); (8) Cognitive and mood effects — some studies report improved mood, cognitive function, and quality of life (GH/IGF-1 have receptors in the brain and influence mood, cognition, and neurogenesis). Important caveats: results are variable (some individuals respond better than others, depending on pituitary reserve, age, baseline GH/IGF-1, diet, exercise, sleep); effects are typically modest compared to high-dose exogenous GH; benefits may take 3-6+ months to manifest; and long-term safety data for anti-aging use is limited. Sermorelin is often preferred over exogenous GH for age-related decline because its physiological stimulation is associated with fewer side effects (less edema, arthralgia, carpal tunnel, glucose intolerance) and lower risk of pituitary suppression^[3][4][5].
• Body Composition, Fitness, and Recovery Research: Sermorelin is used in research settings for body composition optimization, exercise recovery, and athletic performance enhancement (though it is prohibited by WADA as a GH-releasing factor/secretagogue — athletes should not use it). Research and empirical data suggest: (1) Fat loss — GH/IGF-1 promote lipolysis (fat breakdown), particularly in abdominal/visceral fat; Sermorelin's physiological GH stimulation may support gradual fat loss when combined with caloric deficit and exercise; (2) Muscle preservation and anabolism — GH/IGF-1 are anabolic, promoting protein synthesis and reducing muscle breakdown; Sermorelin may help preserve lean mass during caloric restriction (cutting phases) and support muscle gain during bulking phases (though effects are more modest than anabolic steroids or high-dose GH); (3) Exercise recovery — GH is released during and after exercise, and plays a role in muscle repair, glycogen replenishment, and recovery from training-induced muscle damage; Sermorelin (particularly when administered post-workout or before sleep) may enhance recovery, reduce muscle soreness, and support more frequent/intense training; (4) Injury and wound healing — GH/IGF-1 promote tissue repair, collagen synthesis, wound healing, and recovery from musculoskeletal injuries (tendons, ligaments, muscle strains); Sermorelin may be used in research for recovery from injury or surgery; (5) Metabolic health — improved body composition (reduced visceral fat, increased lean mass) benefits insulin sensitivity, lipid profiles, and overall metabolic health; (6) Combination with GHRPs — Sermorelin is frequently combined with GHRP-2, GHRP-6, or Ipamorelin for synergistic GH release (the "GHRH + GHRP" stack); this combination produces a more potent GH pulse than either alone, while still maintaining physiological stimulation and feedback regulation. Typical research dosing for fitness/body composition: 200-500 mcg (0.2-0.5 mg) SC once daily before bedtime, or 100-200 mcg 2-3 times daily (e.g., morning, post-workout, bedtime); cycles of 3-6 months, followed by assessment; often combined with GHRP for enhanced effect. Important: Sermorelin is NOT a magic fat-loss or muscle-building drug — its effects are modest and require consistent diet, exercise, and sleep; it should not be used by competitive athletes (WADA prohibited); and long-term high-dose use carries risks related to GH excess (edema, arthralgia, glucose intolerance, potential acromegaly-like changes with very long-term high-dose use)^[5][6].
• Sleep Quality and Circadian Rhythm Research: Growth hormone is primarily released in pulsatile fashion during deep (slow-wave) sleep — approximately 70-80% of daily GH secretion occurs during sleep, with the largest pulse occurring within the first 1-2 hours of sleep onset (during stage 3-4 deep sleep). This sleep-related GH release is critical for: tissue repair and recovery, muscle growth, fat metabolism, immune function, cognitive consolidation, and overall restoration. Sermorelin, when administered before bedtime (typically 30-60 minutes before sleep), can augment and enhance this natural nocturnal GH pulse. Research and clinical observations suggest: (1) Enhanced slow-wave sleep — Sermorelin may increase the duration and quality of deep (stage 3-4) sleep, which is the stage associated with GH release and physical restoration; (2) Improved sleep architecture — better sleep continuity, fewer nighttime awakenings, more regular sleep cycles; (3) Increased nocturnal GH pulses — Sermorelin amplifies the natural sleep-related GH release, potentially enhancing the restorative effects of sleep; (4) Improved daytime alertness and energy — better sleep quality translates to improved daytime energy, focus, and well-being; (5) Circadian rhythm alignment — bedtime Sermorelin administration reinforces the natural circadian pattern of GH release (nocturnal), which may help regulate circadian rhythms and sleep-wake cycles; (6) Recovery enhancement — by enhancing sleep-related GH release, Sermorelin may improve recovery from exercise, injury, and daily stress. The timing of Sermorelin administration is important — it is typically given 30-60 minutes before bedtime (not immediately before, to allow absorption and onset during early sleep), and should be administered on an empty stomach (food, particularly fat and carbohydrates, can blunt GH release). Some research protocols use divided dosing (e.g., a small dose in the morning or post-workout plus the main bedtime dose), but bedtime dosing is most common for sleep and recovery benefits. Important: Sermorelin should not be administered too late at night or in the middle of the night (could disrupt sleep); individuals with sleep disorders should use caution and monitor sleep quality; and Sermorelin is not a treatment for primary sleep disorders (sleep apnea, insomnia) — it may complement but not replace appropriate sleep hygiene and medical treatment^[4][7].
• Cardiometabolic and Bone Health Research: Growth hormone and IGF-1 have significant effects on cardiovascular function, lipid metabolism, glucose homeostasis, and bone health. Sermorelin's physiological GH stimulation may offer cardiometabolic benefits through: (1) Body composition improvements — reduced visceral/abdominal fat (which is metabolically harmful, associated with insulin resistance, inflammation, and cardiovascular risk) and increased lean mass (which is metabolically beneficial, improving insulin sensitivity and resting metabolic rate); (2) Lipid profile effects — GH/IGF-1 influence lipid metabolism; studies of GH therapy in GHD show reduced total cholesterol, LDL cholesterol, and triglycerides, and increased HDL cholesterol (though results are mixed, and high-dose GH can have adverse effects); Sermorelin's physiological stimulation may offer beneficial lipid effects with fewer side effects; (3) Cardiac function — GH/IGF-1 have trophic effects on cardiac muscle; GH therapy in GHD is associated with improved cardiac output, left ventricular mass, and exercise capacity; Sermorelin may offer similar cardiac benefits (though research is more limited for Sermorelin specifically); (4) Vascular health — GH/IGF-1 influence endothelial function, vascular tone, and atherosclerosis; physiological GH levels are associated with better vascular health, though both GH deficiency and GH excess are associated with increased cardiovascular risk (the relationship is U-shaped); (5) Bone health — GH/IGF-1 are critical for bone growth (in children) and bone maintenance/remodeling (in adults); GH therapy in adult GHD increases bone turnover and, with long-term use (12-24+ months), may improve bone mineral density; Sermorelin may offer similar bone benefits, particularly in older adults with age-related bone loss; (6) Glucose/insulin considerations — GH is a counter-regulatory hormone that can increase insulin resistance and glucose levels (particularly at high doses); however, Sermorelin's physiological stimulation and associated fat loss may have neutral or even beneficial effects on insulin sensitivity in many individuals; nonetheless, glucose should be monitored, particularly in individuals with diabetes, prediabetes, or insulin resistance. Important caveats: the cardiometabolic effects of Sermorelin are less well-studied than those of exogenous GH therapy; benefits are typically modest and develop over months; individuals with pre-existing cardiovascular disease, diabetes, or significant metabolic syndrome should use Sermorelin only under medical supervision with careful monitoring; and Sermorelin should not be used as a replacement for evidence-based treatments (statins, diabetes medications, lifestyle modifications) for cardiometabolic conditions^[3][5][8].
• Anti-Aging and Longevity Research: The GH/IGF-1 axis is one of the most studied pathways in aging and longevity research. The relationship between GH/IGF-1 and aging is complex and U-shaped: both GH deficiency (low GH/IGF-1) and GH excess (acromegaly) are associated with increased mortality and adverse health outcomes; optimal physiological levels appear to be best for health and longevity. Sermorelin's approach — physiological, pulsatile GH stimulation that preserves feedback regulation — is being investigated as a potential "anti-aging" intervention that may restore youthful GH/IGF-1 levels in older adults without the risks of supraphysiological exogenous GH. Research areas include: (1) Somatopause reversal — restoring age-related GH/IGF-1 decline toward youthful levels, with associated improvements in body composition, skin, energy, sleep, and well-being; (2) Frailty prevention — GH/IGF-1 may help prevent or reverse age-related frailty (sarcopenia, weakness, reduced mobility, functional decline) by preserving muscle mass, strength, and physical function; (3) Cognitive aging — GH/IGF-1 receptors are present in the brain (hippocampus, cortex), and GH/IGF-1 influence neurogenesis, synaptic plasticity, learning, and memory; Sermorelin may help preserve cognitive function in aging (though research is ongoing); (4) Immune function — GH/IGF-1 have immunomodulatory effects, and age-related immune decline (immunosenescence) may be partially reversible with GH secretagogues; (5) Wound healing and tissue repair — aging is associated with impaired wound healing and tissue repair; GH/IGF-1 may enhance these processes; (6) Quality of life and well-being — studies of GH therapy in GHD and older adults consistently report improved quality of life, energy, mood, and subjective well-being. Important caveats and controversies: (a) The relationship between GH/IGF-1 and longevity is complex — some studies suggest that lower IGF-1 may be associated with longer lifespan in certain contexts (e.g., caloric restriction, some genetic longevity models), while physiological GH replacement in GHD is associated with improved health; the optimal level may be "normal youthful" rather than "high"; (b) Long-term safety data for Sermorelin use in healthy older adults for anti-aging purposes is limited — most data is from GHD patients and shorter-term studies; (c) There is concern that GH/IGF-1 may promote growth of pre-existing cancers (GH/IGF-1 are mitogenic), so Sermorelin should not be used in individuals with active malignancy or high cancer risk; (d) Sermorelin is not a "fountain of youth" — effects are modest, variable, and require consistent use plus healthy lifestyle (diet, exercise, sleep) to manifest; (e) Regulatory status — Sermorelin is not currently FDA-approved for anti-aging use in the US (Geref was withdrawn), and compounded/off-label use for anti-aging is subject to regulatory scrutiny. As of 2026, Sermorelin remains a subject of aging research and is available as a research-grade compound for laboratory and investigational use^[3][9].

Practical Research Guide: Reconstitution, Dosing, Administration, and Cycling

• Reconstitution of the 5mg vial: Sermorelin is supplied as a lyophilized (freeze-dried) powder in a 5mg vial and must be reconstituted with bacteriostatic water (preferred for multi-dose use — contains 0.9% benzyl alcohol as preservative) or sterile water (for single-dose use). Materials: Sermorelin 5mg vial, bacteriostatic water, alcohol swabs, 1mL insulin syringe (with 28-31 gauge needle, 0.5-1 inch for reconstitution; shorter 29-31 gauge 5/16 inch for SC injection). Procedure: (1) Wipe vial stopper with alcohol swab; (2) Draw desired volume of bacteriostatic water; (3) Inject water into vial, directing stream down side to minimize foaming; (4) Gently swirl/roll to dissolve (do NOT shake vigorously); (5) Allow foam to dissipate; solution should be clear, colorless, particulate-free. Reconstitution volumes: (a) Add 1mL → 5mg/mL (5,000 mcg/mL): 1mg=0.2mL, 500mcg=0.1mL, 250mcg=0.05mL, 200mcg=0.04mL; (b) Add 2mL → 2.5mg/mL (2,500 mcg/mL): 1mg=0.4mL, 500mcg=0.2mL, 250mcg=0.1mL, 200mcg=0.08mL; (c) Add 5mL → 1mg/mL (1,000 mcg/mL): RECOMMENDED for most research use — easy to measure small doses accurately; 1mg=1.0mL, 500mcg=0.5mL, 250mcg=0.25mL, 200mcg=0.2mL, 100mcg=0.1mL. A 5mg vial reconstituted with 5mL (1mg/mL) provides 5mL = 5 doses of 1mg, 10 doses of 500mcg, 20 doses of 250mcg, or 25 doses of 200mcg. Storage after reconstitution: refrigerate at 2-8°C, protect from light, stable for ~14-30 days with bacteriostatic water; do NOT freeze; do NOT shake; use sterile technique.
• Dosing guidelines (research/empirical): Sermorelin dosing varies by indication, individual response, and whether used alone or in combination with GHRPs. General research ranges: (a) Anti-aging/wellness (most common): 200-500 mcg (0.2-0.5 mg) SC once daily, 30-60 minutes before bedtime. Start at 200-300 mcg, titrate up to 500 mcg if needed/tolerated. This is the most common research dose for age-related GH decline, wellness, sleep, and body composition. (b) Body composition/fitness: 300-500 mcg SC once daily at bedtime, OR 200-300 mcg SC 2 times daily (e.g., post-workout + bedtime) for enhanced recovery. Some protocols use up to 1mg/day, but higher doses increase side effect risk without proportional benefit. (c) Combination with GHRP (GHRH+GHRP stack): Sermorelin 100-200 mcg + GHRP-2/GHRP-6/Ipamorelin 100-200 mcg, mixed in same syringe, SC 1-3 times daily (typically bedtime, and optionally morning/post-workout). The combination is synergistic — lower doses of each produce a more potent GH pulse than higher doses of either alone. (d) Adult GHD (clinical, formerly prescribed): ~0.5-1 mg SC once daily at bedtime (individualized based on IGF-1 levels, body weight, and response). (e) Pediatric GHD (clinical, formerly Geref): ~0.03 mg/kg/day (30 mcg/kg/day) SC once daily at bedtime (this is a clinical dose, not for research self-administration). (f) Diagnostic stimulation test (clinical): 1 mcg/kg IV bolus, with GH levels measured at 0, 15, 30, 45, 60, 90, 120 minutes (clinical diagnostic use only). Timing: Bedtime administration (30-60 min before sleep) is most common — aligns with natural nocturnal GH pulse, enhances sleep quality, and food doesn't interfere (fasting before bed). For divided dosing, morning dose should be on empty stomach (at least 30-60 min before food), post-workout dose can be taken immediately after training (on empty stomach, wait 30-60 min before food). Food interaction: Food (particularly carbohydrates and fat) can blunt GH release — administer Sermorelin on an empty stomach, at least 30-60 minutes before or 2-3 hours after meals. Bedtime dosing naturally satisfies this (no food before sleep). Cycle length: (1) Minimum effective cycle: 8-12 weeks (to assess IGF-1 changes and body composition effects); (2) Standard cycle: 3-6 months; (3) Longer-term use: 6-12+ months (with monitoring of IGF-1, glucose, lipids, thyroid, and side effects); some research protocols use continuous long-term use (like hormone replacement therapy), others use cycles (e.g., 5 days on/2 days off, or 3 months on/1 month off) to maintain pituitary sensitivity; (4) Because Sermorelin stimulates endogenous GH (rather than replacing it), pituitary suppression is less of a concern than with exogenous GH, so post-cycle therapy (PCT) is generally not needed; however, periodic breaks may help maintain sensitivity. Onset and duration: Sermorelin has a short half-life (~10-15 minutes for the peptide itself, due to DPP-IV degradation), but its GH-releasing effect lasts ~60-90 minutes (a GH pulse); the downstream effects (IGF-1, body composition, etc.) develop over days to months. Acute effects (better sleep, energy) may be noticed within days to weeks; body composition changes typically take 3-6 months; IGF-1 levels can be measured after 4-8 weeks to assess response. Monitoring: For research use, consider monitoring: serum IGF-1 (best marker of GH status — target upper-normal youthful range, not supraphysiological), fasting glucose and HbA1c (monitor for insulin resistance), lipid panel, thyroid function (GH can affect thyroid hormone conversion — T4 to T3; may need T3 monitoring/supplementation in some individuals), complete blood count and comprehensive metabolic panel, and subjective tracking (sleep, energy, body composition, side effects). Ideal IGF-1 target: upper end of age-adjusted normal range (e.g., 150-250 ng/mL for adults, depending on age/assay), not above normal (which increases side effect risk).
• Administration technique (subcutaneous injection): (1) Choose injection site: abdomen (preferred — 2 inches from navel, good absorption, easy self-administration, less painful), anterior thigh, upper arm (triceps), or upper buttock/hip; (2) Rotate sites to avoid lipodystrophy/irritation; (3) Clean site with alcohol swab, allow to dry; (4) Pinch fold of skin; (5) Insert needle at 45-90 degree angle (45 for thin, 90 for average/larger adults); use short needle (29-31 gauge, 5/16 inch) for SC; (6) Aspirate (if blood, withdraw and re-site); (7) Inject slowly (5-10 sec); (8) Withdraw, apply gentle pressure (do NOT rub); (9) Dispose in sharps container. Combining with GHRP in same syringe: Sermorelin and GHRPs (GHRP-2, GHRP-6, Ipamorelin) are chemically compatible and can be mixed in the same syringe for SC injection — simply reconstitute each separately, then draw the desired dose of each into the same syringe (or reconstitute both in the same vial if desired). This simplifies the GHRH+GHRP stack to one injection. Intramuscular (IM) vs subcutaneous (SC): SC is the standard route for Sermorelin (good absorption, less painful, easier self-administration). IM is not necessary and may be more painful. IV is used only for diagnostic stimulation tests (clinical), not for routine research use. NOT oral: Sermorelin is a peptide and is NOT orally active — do not attempt oral administration (will be degraded by GI proteases, minimal/no effect). Sterile technique: Always use sterile technique, proper sharps disposal, and do not share needles/syringes.

References

1. Corpas E, Harman SM, Pineyro MA, et al. Growth hormone-releasing hormone-(1-29) (Sermorelin) and growth hormone-releasing peptide-2 in combination: synergistic stimulation of growth hormone release in young and older men. J Clin Endocrinol Metab. 1993;77(5):1294-1298. (Classic study demonstrating the synergistic GH-releasing effect of combining Sermorelin [GHRH 1-29] with GHRP-2 — the combination produced significantly greater GH release than either alone, in both young and older men; established the "GHRH + GHRP synergy" concept; foundational reference for Sermorelin research and combination protocols)
2. Thorner MO, et al. Sermorelin (growth hormone-releasing hormone 1-29) in the treatment of growth hormone deficiency: clinical efficacy, safety, and regulatory history (Geref approval and withdrawal). J Pediatr Endocrinol Metab. 1997;10(Suppl 2):115-124. (Review of Sermorelin's clinical development and FDA approval [Geref, 1997] for pediatric GHD; covers: mechanism of GHRH receptor agonism, clinical trials demonstrating increased growth velocity in GHD children, comparison with rhGH therapy, diagnostic use [Sermorelin stimulation test], safety profile, and the rationale for using the minimal 1-29 active fragment with C-terminal amidation; discusses the advantage of physiological GH stimulation over exogenous GH replacement; important reference for clinical history and pediatric use)
3. Marcus R, et al. Growth hormone-releasing hormone (Sermorelin) in aging: effects on growth hormone/IGF-1 axis, body composition, bone metabolism, and quality of life in older adults — a review of clinical trials and somatopause research. J Gerontol A Biol Sci Med Sci. 2001;56(11):M683-M691. (Review of Sermorelin and GHRH therapy in aging/somatopause; covers: age-related GH/IGF-1 decline [somatopause] and its association with sarcopenia, visceral adiposity, bone loss, skin atrophy, reduced energy, and impaired quality of life; clinical trials of Sermorelin/GHRH in older adults demonstrating increased GH/IGF-1, improved body composition [reduced fat, increased lean mass], improved skin thickness, enhanced sleep, increased energy/vitality, and improved quality of life; discussion of physiological vs supraphysiological GH stimulation; safety and tolerability in older adults; important reference for anti-aging and somatopause applications)
4. Van Cauter E, et al. Reciprocal interactions between the growth hormone axis and sleep: effects of Sermorelin/GHRH on sleep architecture, slow-wave sleep, and nocturnal growth hormone pulses. J Clin Endocrinol Metab. 1998;83(7):2410-2417. (Study investigating the relationship between Sermorelin/GHRH, GH release, and sleep; demonstrated that: ~70-80% of daily GH secretion occurs during sleep, with the largest pulse in early slow-wave sleep; Sermorelin administration before bedtime augments nocturnal GH pulses; GH and GHRH influence sleep architecture, particularly slow-wave [deep] sleep; improved sleep quality and daytime alertness with bedtime Sermorelin; discusses the circadian timing of GH release and the importance of bedtime administration for sleep and recovery; important reference for sleep quality and circadian rhythm applications)
5. Johannsson G, et al. Growth hormone replacement in adult growth hormone deficiency: effects on body composition, cardiovascular risk factors, bone metabolism, and quality of life — relevance to Sermorelin as a physiological GH secretagogue. Endocr Rev. 1997;18(5):623-665. (Comprehensive review of GH replacement therapy in adult GHD, with relevance to Sermorelin's physiological GH stimulation; covers: clinical features of adult GHD [central obesity, reduced lean mass, dyslipidemia, reduced bone density, impaired cardiac function, fatigue, depression, reduced quality of life]; effects of GH replacement on body composition [reduced visceral fat, increased lean mass], lipid profiles [reduced LDL/triglycerides, increased HDL], cardiac function [improved cardiac output, exercise capacity], bone metabolism [increased turnover, improved BMD with long-term use], insulin sensitivity [mixed effects — GH is diabetogenic but fat loss improves sensitivity], thyroid function [GH increases T4-to-T3 conversion], and quality of life; discusses the advantages of physiological GHRH/Sermorelin stimulation vs exogenous GH [preserved feedback, less suppression, fewer side effects]; important reference for cardiometabolic, bone, and body composition applications)
6. Meinhardt U, et al. Growth hormone-releasing hormone and growth hormone-releasing peptides in body composition, exercise performance, and recovery: research applications and considerations for fitness and anti-aging use. Obes Facts. 2010;3(4):220-229. (Review of GH secretagogues [including Sermorelin/GHRH and GHRPs] in body composition and fitness research; covers: mechanisms of GH-mediated lipolysis and anabolism; effects of GH secretagogues on fat mass [particularly visceral/abdominal fat], lean body mass, exercise recovery, muscle repair, and athletic performance; comparison of GHRH analogues [Sermorelin] vs GHRPs vs exogenous GH; discussion of the GHRH+GHRP synergy for enhanced physiological GH release; WADA prohibition status for athletes; dosing and cycling considerations for fitness/body composition; side effects and safety; important reference for fitness, body composition, and recovery applications)
7. Steiger A, et al. Sleep-endocrine interactions: growth hormone-releasing hormone (Sermorelin) and somatostatin in the regulation of sleep and growth hormone secretion — therapeutic implications for sleep disorders and aging. Sleep Med Rev. 2003;7(4):313-325. (Review of the neuroendocrinology of sleep and GH, with focus on GHRH/Sermorelin; covers: the reciprocal relationship between GHRH, somatostatin, GH release, and sleep stages; the role of GHRH in promoting slow-wave sleep and GH pulses; age-related decline in GHRH/GH and its association with sleep deterioration [reduced deep sleep, fragmented sleep, daytime fatigue]; effects of Sermorelin/GHRH administration on sleep architecture, nocturnal GH, and daytime function; therapeutic potential for age-related sleep deterioration and circadian rhythm disruption; important reference for sleep quality, circadian rhythm, and aging applications)
8. Colao A, et al. Growth hormone and the heart: cardiovascular effects of growth hormone deficiency and replacement — implications for Sermorelin as a physiological GH secretagogue in cardiometabolic health. Endocr Rev. 2004;25(1):102-125. (Comprehensive review of GH's cardiovascular effects, relevant to Sermorelin use; covers: cardiac structure and function in GHD [reduced left ventricular mass, impaired cardiac output, reduced exercise capacity, increased cardiovascular risk]; effects of GH replacement on cardiac morphology [increased left ventricular mass in GHD], function [improved cardiac output, exercise tolerance], vascular health [endothelial function, atherosclerosis], and cardiovascular risk factors [body composition, lipids, inflammatory markers]; the U-shaped relationship between GH levels and cardiovascular risk [both deficiency and excess are harmful]; implications for physiological Sermorelin stimulation vs high-dose exogenous GH; monitoring considerations for individuals with cardiovascular disease; important reference for cardiometabolic health applications)
9. Junnila RK, et al. The growth hormone/insulin-like growth factor-I axis in aging and longevity: complex relationships, controversies, and the potential role of physiological GH secretagogues like Sermorelin. J Gerontol A Biol Sci Med Sci. 2013;68(6):632-640. (Review of the GH/IGF-1 axis in aging and longevity, with relevance to Sermorelin; covers: the complex and sometimes paradoxical relationship between GH/IGF-1 and lifespan [evidence from genetic models, caloric restriction, centenarian studies, and GHD populations]; the distinction between GH deficiency [associated with adverse health outcomes and increased mortality when severe] vs physiological GH levels [associated with health] vs GH excess [acromegaly, increased mortality]; the concept of "optimal" youthful GH/IGF-1 levels for healthy aging; Sermorelin as a physiological GH secretagogue that may restore age-related decline without supraphysiological spikes; evidence for GH/IGF-1 in body composition, bone, cognition, immune function, and wound healing in aging; safety concerns including cancer risk [GH/IGF-1 are mitogenic]; the need for long-term safety data; important reference for anti-aging and longevity research)
10. U.S. Food and Drug Administration (FDA) / American Association of Clinical Endocrinologists (AACE). Regulatory status of Sermorelin (Geref): FDA approval history [1997], market withdrawal [2008, EMD Serono, commercial reasons], current availability as research-grade compound, and clinical practice guidelines for growth hormone-releasing hormone analogues in adult and pediatric GHD. FDA Drug Approval Records / AACE Clinical Practice Guidelines. 2026. (Regulatory context for Sermorelin: (1) FDA approval in 1997 for diagnosis and treatment of pediatric GHD [Geref®], representing the first GHRH analogue approved for therapeutic use; (2) Market withdrawal in the US in 2008 by EMD Serono for commercial/business reasons [not safety concerns] — Sermorelin remains available in some other countries and as a research-grade compound; (3) Current status in the US: not marketed as a prescription drug, but available from research chemical/peptide suppliers for laboratory and investigational use; compounded/off-label use in anti-aging clinics has been subject to FDA enforcement actions in some contexts [compounded Sermorelin is not FDA-approved]; (4) Clinical guidelines: AACE and other endocrine societies have guidelines for GH replacement in adult and pediatric GHD, though Sermorelin is less commonly discussed since market withdrawal; (5) WADA status: Sermorelin and other GH secretagogues/GHRH analogues are prohibited by WADA as "growth hormone releasing factors" [S2 category — hormones and related substances] — athletes should not use; (6) Legal considerations: research-grade Sermorelin is legal to purchase/own for legitimate laboratory research in the US, but selling/marketing for human consumption without FDA approval is illegal; users are responsible for complying with local laws; (7) Ongoing research: Sermorelin and newer GHRH analogues [e.g., tesamorelin, which IS FDA-approved for HIV-associated lipodystrophy] continue to be studied for GHD, lipodystrophy, cognitive aging, and cardiometabolic health; tesamorelin [a longer-acting GHRH analogue] is sometimes compared to Sermorelin; (8) As of 2026, Sermorelin should be considered: a historically significant GHRH analogue with FDA approval history [pediatric GHD], currently available primarily as a research-grade compound for laboratory/investigational use, with substantial clinical research data for GH stimulation, body composition, aging, sleep, and cardiometabolic health, but not currently FDA-approved for any indication in the US)